NZ208950A - Pharmaceutical composition containing dipropylacetic acid and a salt thereof - Google Patents
Pharmaceutical composition containing dipropylacetic acid and a salt thereofInfo
- Publication number
- NZ208950A NZ208950A NZ208950A NZ20895084A NZ208950A NZ 208950 A NZ208950 A NZ 208950A NZ 208950 A NZ208950 A NZ 208950A NZ 20895084 A NZ20895084 A NZ 20895084A NZ 208950 A NZ208950 A NZ 208950A
- Authority
- NZ
- New Zealand
- Prior art keywords
- valproic acid
- pharmaceutical composition
- tablets
- excipient
- active principle
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims description 146
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 150000003839 salts Chemical class 0.000 title claims description 12
- 229960000604 valproic acid Drugs 0.000 claims description 59
- 229940084026 sodium valproate Drugs 0.000 claims description 34
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 238000007906 compression Methods 0.000 claims description 14
- 230000006835 compression Effects 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 10
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 10
- 241001125671 Eretmochelys imbricata Species 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005054 agglomeration Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002124 flame ionisation detection Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- SRGJYZBCRLBAEN-UHFFFAOYSA-M sodium;1-methylcyclohexane-1-carboxylate Chemical compound [Na+].[O-]C(=O)C1(C)CCCCC1 SRGJYZBCRLBAEN-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8312376A FR2549374B1 (fr) | 1983-07-20 | 1983-07-20 | Compositions medicamenteuses a base d'acide valproique modifiant favorablement leur cinetique et leur procede de fabrication galenique |
| FR8312375A FR2549370B1 (fr) | 1983-07-20 | 1983-07-20 | Nouvelle composition pharmaceutique a base d'acide valproique et son procede de fabrication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ208950A true NZ208950A (en) | 1987-09-30 |
Family
ID=26223536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ208950A NZ208950A (en) | 1983-07-20 | 1984-07-19 | Pharmaceutical composition containing dipropylacetic acid and a salt thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5017613A (enExample) |
| EP (1) | EP0133110B1 (enExample) |
| JP (1) | JPH0696524B2 (enExample) |
| KR (1) | KR850000975A (enExample) |
| AU (1) | AU563383B2 (enExample) |
| CA (1) | CA1220718A (enExample) |
| DE (1) | DE3469342D1 (enExample) |
| DK (1) | DK161185C (enExample) |
| GR (1) | GR79979B (enExample) |
| IL (1) | IL72381A (enExample) |
| NZ (1) | NZ208950A (enExample) |
| PH (1) | PH21506A (enExample) |
| SG (1) | SG52088G (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| JPH0667828B2 (ja) * | 1985-10-09 | 1994-08-31 | 日研化学株式会社 | バルプロ酸ナトリウムの持続性顆粒製剤 |
| SE8505569D0 (sv) * | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
| IT1213508B (it) * | 1986-10-22 | 1989-12-20 | Foscama Biomed Chim Farma | Preparato farmaceutico a base di buflomedil cloridrato, sotto formadi compresse a rilascio controllato e relativo procedimento di preparazione. |
| US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
| US5268182A (en) * | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
| FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| DE69327745T2 (de) * | 1992-05-29 | 2000-09-21 | Nikken Chemicals Co., Ltd. | Tablette zur langsamen Freisetzung von Natriumvalproat |
| US6287598B1 (en) * | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| NZ270438A (en) * | 1995-02-02 | 1996-03-26 | Bernard Charles Sherman | Solid (granular) mixture of valproic acid (di-n-propyl acetic acid) and its sodium salt; pharmaceutical compositions |
| MX9707585A (es) * | 1995-04-03 | 1997-12-31 | Abbott Lab | Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada. |
| JPH09323926A (ja) * | 1996-03-15 | 1997-12-16 | Nikken Chem Co Ltd | バルプロ酸ナトリウムの徐放性錠剤 |
| FR2754177B1 (fr) * | 1996-10-07 | 1999-08-06 | Sanofi Sa | Microspheres pharmaceutiques d'acide valproique pour administration orale |
| DE19840152A1 (de) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung |
| AR020343A1 (es) * | 1998-11-24 | 2002-05-08 | Steigerwald Arzlneimittelwerk | Metodo para producir farmacos que contienen extractos de plantas en una forma solida de aplicacion. |
| US6419953B1 (en) * | 1998-12-18 | 2002-07-16 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6511678B2 (en) | 1998-12-18 | 2003-01-28 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6528090B2 (en) | 1998-12-18 | 2003-03-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US20020031549A1 (en) * | 1998-12-18 | 2002-03-14 | Yihong Qiu | Controlled release formulation of divalproex sodium |
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| WO2000045793A1 (en) * | 1999-02-04 | 2000-08-10 | Abbott Laboratories | Ph independent extended release pharmaceutical formulation |
| US6150410A (en) * | 1999-02-04 | 2000-11-21 | Abbott Laboratories | pH independent extended release pharmaceutical formulation |
| US6753349B1 (en) | 1999-11-02 | 2004-06-22 | Cilag Ag | Method of preparing valproinic acid compounds |
| US20020132010A1 (en) * | 2000-12-22 | 2002-09-19 | Yihong Qui | Divalproex sodium dosage forms and a process for their production |
| US20020143058A1 (en) | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
| US20040105886A1 (en) * | 2001-02-16 | 2004-06-03 | Chih-Ming Chen | Divalproex sodium tablets |
| US6610326B2 (en) | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| WO2003103635A1 (en) * | 2002-06-07 | 2003-12-18 | Ranbaxy Laboratories Limited | Extended release formulation of divalproex sodium |
| EP1567674A4 (en) | 2002-11-22 | 2007-09-26 | Univ Johns Hopkins | AIM FOR THE THERAPY OF COGNITIVE IMMUNITY |
| US20050276849A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release dosage forms |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
| NZ555693A (en) * | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| HK1081802A2 (en) * | 2005-09-09 | 2006-05-19 | 林子深 | Intelligent crossroad |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| BRPI0920342A2 (pt) | 2008-10-16 | 2020-06-23 | The Johns Hopkins University | Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo |
| EP2533645B1 (en) * | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| KR101733189B1 (ko) * | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
| GB201020133D0 (en) | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| CN106456681B (zh) * | 2014-06-10 | 2019-11-22 | 狮王株式会社 | 含有清酒酵母的片剂 |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| CN108578678A (zh) * | 2018-03-13 | 2018-09-28 | 孟斯琴 | 一种抗癫痫药物组合物及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB760114A (en) * | 1953-06-19 | 1956-10-31 | Chimie Atomistique | Improvements in and relating to compositions for lowering the cholesterol level in the blood serum |
| FR2442M (fr) * | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
| FR2077918B1 (enExample) * | 1970-02-24 | 1973-04-06 | Berthier Laboratoires | |
| NL7115745A (en) * | 1971-11-16 | 1973-05-18 | Dipropylacetic acid derivs - as anticonvulsants, tranquillizers muscle relaxants, antipyretics and diuretics | |
| FR2383907A1 (fr) * | 1977-03-15 | 1978-10-13 | Labaz | Procede de preparation de derives de l'acide acetique et derives obtenus par ce procede |
| IL59407A (en) * | 1979-03-06 | 1983-12-30 | Sanofi Sa | Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them |
| US4654370A (en) * | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
| IT1121282B (it) * | 1979-06-08 | 1986-04-02 | Medea Res Srl | Composto ad attivita'antiepilettica e anticonvulsivante,processo per la sua preparazione e composizioni farmaceutiche relative |
| DE3063328D1 (en) * | 1979-08-20 | 1983-07-07 | Abbott Lab | Mixed salt of valproic acid |
| US4301176A (en) * | 1980-08-18 | 1981-11-17 | Warner-Lambert Company | Method of administering calcium valproate |
| LU83729A1 (fr) * | 1981-11-04 | 1983-09-01 | Galephar | Sels d'acide valproique,leur preparation et leur utilisation |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| FR2547499A1 (fr) * | 1983-06-15 | 1984-12-21 | Opochimiotherapie Lab | Medicaments contenant du dipropylacetate de calcium |
| FR2549371B1 (fr) * | 1983-07-20 | 1985-09-13 | Sanofi Sa | Nouvelle composition pharmaceutique contenant de l'acide valproique ou un de ses sels |
| US4558070A (en) * | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4913906B1 (en) * | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
| DE3709230A1 (de) * | 1987-03-20 | 1988-10-06 | Desitin Arzneimittel Gmbh | Neues calciumsalz der valproinsaeure |
-
1984
- 1984-07-11 IL IL72381A patent/IL72381A/xx not_active IP Right Cessation
- 1984-07-13 CA CA000458903A patent/CA1220718A/fr not_active Expired
- 1984-07-17 AU AU30755/84A patent/AU563383B2/en not_active Expired
- 1984-07-17 PH PH30992A patent/PH21506A/en unknown
- 1984-07-18 DE DE8484401514T patent/DE3469342D1/de not_active Expired
- 1984-07-18 DK DK351984A patent/DK161185C/da not_active IP Right Cessation
- 1984-07-18 EP EP84401514A patent/EP0133110B1/fr not_active Expired
- 1984-07-19 GR GR75372A patent/GR79979B/el unknown
- 1984-07-19 NZ NZ208950A patent/NZ208950A/en unknown
- 1984-07-20 KR KR1019840004277A patent/KR850000975A/ko not_active Ceased
- 1984-07-20 JP JP59151127A patent/JPH0696524B2/ja not_active Expired - Lifetime
-
1988
- 1988-08-03 SG SG520/88A patent/SG52088G/en unknown
-
1989
- 1989-02-21 US US07/313,304 patent/US5017613A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GR79979B (enExample) | 1984-10-31 |
| DK351984A (da) | 1985-01-21 |
| EP0133110A1 (fr) | 1985-02-13 |
| DK161185B (da) | 1991-06-10 |
| IL72381A0 (en) | 1984-11-30 |
| PH21506A (en) | 1987-11-10 |
| DK351984D0 (da) | 1984-07-18 |
| IL72381A (en) | 1988-03-31 |
| SG52088G (en) | 1989-01-27 |
| US5017613A (en) | 1991-05-21 |
| DE3469342D1 (en) | 1988-03-24 |
| JPH0696524B2 (ja) | 1994-11-30 |
| KR850000975A (ko) | 1985-03-14 |
| JPS6041610A (ja) | 1985-03-05 |
| AU563383B2 (en) | 1987-07-09 |
| CA1220718A (fr) | 1987-04-21 |
| EP0133110B1 (fr) | 1988-02-17 |
| AU3075584A (en) | 1985-01-24 |
| DK161185C (da) | 1991-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ208950A (en) | Pharmaceutical composition containing dipropylacetic acid and a salt thereof | |
| US5185159A (en) | Pharmaceutical composition based on valproic acid and a process for preparing it | |
| US4650664A (en) | Oral mopidamol preparation | |
| US6375987B1 (en) | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix | |
| US4427648A (en) | Dipyridamole-containing pharmaceutical form | |
| JP3382940B2 (ja) | 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤 | |
| US6194005B1 (en) | Method for preparing a pharmaceutical composition with modified release of the active principle, comprising a matrix | |
| JPH05221854A (ja) | 水溶性薬物を含有する制御的放出錠剤 | |
| NZ227032A (en) | Stabilised ace inhibitors, a process for their preparation and stable pharmaceutical compositions therefrom | |
| IE904091A1 (en) | Sustained-release drug dosage units | |
| JPH02270820A (ja) | 徐放性エトドラク | |
| EA021784B1 (ru) | Фармацевтические композиции с длительным высвобождением | |
| AU748396B2 (en) | Composition | |
| JP2003528905A (ja) | スタブジン含有持続放出性ビーズ剤 | |
| WO2018065826A1 (en) | Multilayer beads for pharmaceutical use | |
| WO1997033574A1 (fr) | Comprimes a liberation prolongee a base de valproate metallique | |
| JPWO1997033574A1 (ja) | バルプロ酸金属塩の徐放性錠剤 | |
| JP2018104324A (ja) | 徐放性製剤 | |
| EP0952823B1 (en) | Stabilized pharmaceutical compositions and process for the preparation thereof | |
| RU2236231C2 (ru) | Таблетка циклофосфамида с пленочным покрытием (варианты) и способ ее получения, ядро таблетки и способ его получения | |
| US20100021393A1 (en) | Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate | |
| JPH11180875A (ja) | テオフィリン徐放性錠剤及びその製造方法 | |
| JP2022112698A (ja) | アピキサバン含有医薬組成物 | |
| US20020142037A1 (en) | Process for the manufacture of a pharmaceutical composition with modified release of active principle comprising a matrix | |
| KR20230136513A (ko) | 비타민 c의 안정한 서방성 제형 및 이의 제조 방법 |